SFI
PCVX icon

Susquehanna Fundamental Investments’s Vaxcyte PCVX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,732
Closed -$205K – 1596
2020
Q4 		$205K Sell
7,732
-1,927
-20% -$71.6K ﹤0.01% 1352
2020
Q3 		$477K Buy
+9,659
New +$385K 0.01% 893

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna Fundamental Investments's PCVX Position: Q1 2021 in Review

Susquehanna Fundamental Investments sold out of Vaxcyte (PCVX) in Q1 2021, closing a stake of 7,732 shares — an estimated $205K sold.

Susquehanna Fundamental Investments first reported a position in PCVX in Q3 2020 and held it in 2 quarters. The position peaked at $477K in Q3 2020. 74 funds tracked by Wall St. Rank hold PCVX as of Q1 2021.

  • Susquehanna Fundamental Investments reported no remaining Vaxcyte position as of Q1 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 7,732 Vaxcyte shares in Q1 2021, an estimated $205K.
  • Susquehanna Fundamental Investments first reported a position in Vaxcyte in Q3 2020 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Vaxcyte position peaked at $477K in Q3 2020.
  • 74 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2021, filed 17 May 2021.